EBV阳性弥漫大B细胞淋巴瘤非特指型:2024年诊断、风险分层与管理更新
EBV阳性弥漫大B细胞淋巴瘤非特指型(EBV+ DLBCL, NOS)是一种与EBV感染相关的侵袭性B细胞淋巴瘤,自2016年起纳入WHO淋巴系统肿瘤分类。诊断依赖病理评估和EBER检测,ICC 2022规定EBER阳性恶性细胞>80%方可诊断,而WHO-HAEM5强调多数肿瘤细胞EBER阳性但未设定明确阈值。风险分层可用IPI和Oyama评分(年龄>70岁和B症状)。管理上应按EBV阴性DLBCL的指南进行分期和治疗,但化疗免疫治疗时代EBV+ DLBCL, NOS预后可能仍较差,推荐患者入组临床试验,并有机会研究靶向治疗。
要点
- 诊断EBV+ DLBCL, NOS需病理评估和EBER检测,ICC 2022要求>80%恶性细胞EBER阳性。
- 风险分层可用IPI和Oyama评分(年龄>70岁和B症状)。
- 管理按EBV阴性DLBCL指南分期治疗,推荐入组临床试验。
核心结论
- EBV+ DLBCL, NOS在化疗免疫治疗时代预后可能仍较EBV阴性DLBCL差,推荐患者入组临床试验,并有机会研究靶向治疗。
研究设计与样本
- 本文为2024年关于EBV+ DLBCL, NOS诊断、风险分层和管理的更新综述。
主要发现
- EBV+ DLBCL, NOS自2016年起纳入WHO淋巴系统肿瘤分类,与EBV感染相关且呈侵袭性。
- 历史上预后较差,但化疗免疫治疗时代结局似乎有所改善。
- CD30和PD-1/PD-L1表达正成为潜在不良但可靶向的生物标志物。
关键数值与推荐
- ICC 2022规定EBV+ DLBCL, NOS的诊断标准为>80%恶性细胞表达EBER。
- WHO-HAEM5强调多数肿瘤细胞应EBER阳性,但未设定明确阈值。
- Oyama评分包括年龄>70岁和存在B症状。
临床怎么用
- EBV+ DLBCL, NOS患者应按EBV阴性DLBCL的指南进行分期和管理。
- 推荐在可行时让患者入组临床试验。
- 有机会研究和发展靶向治疗用于EBV+ DLBCL, NOS患者的管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) is an aggressive B-cell lymphoma associated with EBV infection included in the WHO classification of lymphoid neoplasms since 2016. Although historically associated to poor prognosis, outcomes seem to have improved in the era of chemoimmunotherapy. DIAGNOSIS: The diagnosis is established through meticulous pathological evaluation. Detection of EBV-encoded RNA (EBER) is the standard diagnostic method. The ICC 2022 specifies EBV+ DLBCL, NOS as occurring when >80% of malignant cells express EBER, whereas the WHO-HAEM5 emphasizes that the majority of tumor cells should be EBER positive without setting a defined threshold. The differential diagnosis includes plasmablastic lymphoma, DLBCL associated with chronic inflammation, primary effusion lymphoma, among others. RISK-STRATIFICATION: The International Prognostic Index (IPI) and the Oyama score can be used for risk-stratification. The Oyama score includes age >70 years and presence of B symptoms. The expression of CD30 and PD-1/PD-L1 are emerging as potential adverse but targetable biomarkers. MANAGEMENT: Patients with EBV+ DLBCL, NOS, should be staged and managed following similar guidelines than patients with EBV-negative DLBCL. EBV+ DLBCL, NOS, however, might have a worse prognosis than EBV-negative DLBCL in the era of chemoimmunotherapy. Therefore, inclusion of patients in clinical trials when available is recommended. There is an opportunity to study and develop targeted therapy in the management of patients with EBV+ DLBCL, NOS.
引用
- Malpica L, Marques-Piubelli ML, Beltran BE, et al. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management. Am J Hematol. 2024. PMID: 38957951. doi:10.1002/ajh.27430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。